



Current Agreements

Dealdoc

Collaborative R&D agreement for yeast-based antibody discovery platform to identify fully human antibodies (expanded)

Adimab
Merck and Co

Jun 16 2009

Collaborative R&D agreement for yeast-based antibody discovery platform to identify fully human antibodies (expanded)

Companies:	Adimab Merck and Co
Announcement date:	Jun 16 2009
Amendment date:	Jan 08 2013
Related contracts:	Research and development and licensing option agreement to identify fully human antibodies (expanded) Technology transfer and option agreement for antibody technology

- [Details](#)
- [Financials](#)
- [Termsheet](#)
- [Press Release](#)
- [Filing Data](#)
- [Contract](#)

Details

Announcement date:	Jun 16 2009
Amendment date:	Jan 08 2013
Industry sectors:	Bigpharma Biotech Pharmaceutical Research tools
Technology types:	Antibodies » Bispecific antibodies Antibodies » Monoclonal antibodies
Deal components:	Collaborative R&D
Stages of development:	Discovery

Financials

Milestones, US\$m:	n/d : delivery of a panel of antibodies that meet selection criteria criteria n/d : triggered by achieving development milestone
---------------------------	---

Termsheet

8 January 2013

Adimab announced the expansion of its existing research collaborations with Merck and Lilly.

The latest agreement provides Merck expanded access to Adimab's technology to discover and optimize fully human antibody candidates, including potentially bispecific antibody candidates, across all disease areas.

Adimab scientists will discover therapeutic antibody candidates to multiple targets nominated by Merck over a three-year period.

16 June 2009

Collaboration whereby Adimab will use its proprietary yeast-based antibody discovery platform to identify fully human antibodies against targets selected by Merck.

The agreement grants Merck the right to commercialize antibodies generated from the collaboration as therapeutic products.

8 July 2010

Adimab recieved a second milestone payment from its ongoing collaboration with Merck and Co.

15 December 2010

Adimab announced that Merck has exercised its option to start an additional project around a 2nd target.

Press Release

8 January 2013

Adimab, LLC, a technology leader in the discovery of fully human antibodies, today announced the expansion of its existing research collaborations with Merck and Lilly.

The latest agreement provides Merck expanded access to Adimab's technology to discover and optimize fully human antibody candidates, including potentially bispecific antibody candidates, across all disease areas. Adimab scientists will discover therapeutic antibody candidates to multiple targets nominated by Merck over a three-year period.

Adimab also announced the expansion of its existing research agreement with Lilly to include the discovery and optimization of multiple bispecific antibodies targeting molecular targets identified by Lilly.

Pursuant to these agreements with Merck, acting through a subsidiary, and Lilly, Adimab will receive upfront payments and is eligible to receive preclinical and clinical development milestone payments as well as royalties on product sales.

16 June 2009

Adimab Launches Novel Antibody Discovery Platform and Announces Discovery Programs with Merck and Roche

LEBANON, N.H.--(BUSINESS WIRE)--Adimab, Inc., an emerging leader in the discovery of fully human antibodies, today announced the launch of a unique human antibody discovery platform based on the first fully synthetic human pre-immune IgG repertoire. Adimab's yeast-based platform offers unprecedented epitope coverage and allows for the discovery of high affinity full-length human IgGs in extremely rapid timeframes. In addition, Adimab announced two major research collaborations.

Adimab and Merck, of Whitehouse Station, NJ, have entered into a collaboration whereby Adimab will use its proprietary yeast-based antibody discovery platform to identify fully human antibodies against targets selected by Merck. The agreement grants Merck the right to commercialize antibodies generated from the collaboration as therapeutic products.

In a separate deal, Adimab and Roche, of Basel, Switzerland, have initiated a research program whereby Adimab will use its proprietary yeast-based antibody discovery platform to identify fully human antibodies against a target selected by Roche. The agreement allows Roche the right to commercialize antibodies generated from the collaboration as therapeutic and diagnostic products.

Under the terms of the agreements, Adimab will receive various upfront payments, preclinical milestones and licensing fees. In addition, Adimab is eligible to receive clinical development milestones, commercial milestones and royalties on therapeutic and diagnostic product sales.

"Adimab has developed a disruptive technology in the antibody discovery space," said Tillman Gerngross, Adimab's CEO and co-founder. "The speed, robustness and diversity of our platform will provide drug developers with meaningful advantages over current discovery technologies and we believe this approach has the potential to become a new standard in the industry."

"The execution of discovery agreements with two of the top ten pharmaceutical companies based on Adimab's platform underscores the demand for novel technical approaches and more flexible business solutions in antibody discovery," stated Guy van Meter, Senior Director of Business Development. "We are continuing to get significant traction with potential collaborators and expect the partnering momentum to continue in 2009."

About Adimab

Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements. For more information, visit <http://www.adimab.com>.

8 July 2010

Adimab Announces Fifth Major Pharmaceutical Partnership in First Year After Launch of Novel Antibody Discovery Platform

LEBANON, N.H.--(BUSINESS WIRE)--Adimab, Inc., a leader in the discovery of fully human antibodies, today announced the initiation of a research collaboration with Novartis (Basel, Switzerland). This agreement represents the fifth major partnership Adimab has announced since launching its platform at BIO 2009 in Atlanta, just one year ago.

In addition, Adimab today announced the receipt of a second milestone payment from its ongoing collaboration with Merck and Co.

"Adimab's ability to generate high quality therapeutic leads in less than three months reduces much of the uncertainty of preclinical development and translates into a fundamental competitive advantage for our collaborators," comments Tillman Gerngross, PhD, co-founder and CEO of Adimab.

In the first year after the launch of its antibody discovery platform, Adimab has entered into discovery partnerships with some of the world's premier pharmaceutical companies including Merck, Roche, Pfizer and Novartis. Further, Adimab has received numerous payments related to the successful achievement of key technical milestones in these programs. "With current announced and unannounced contracts, continued revenue from milestone payments and broad interest around Adimab's platform, we expect 2010 to be our first profitable year," notes Errik Anderson, COO of Adimab.

About the Adimab - Novartis Collaboration

Adimab and Novartis, of Basel, Switzerland, have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against two targets selected by Novartis. The agreement gives Novartis rights to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments, preclinical milestones and licensing fees. In addition, Adimab is eligible to receive clinical development milestones and royalties on therapeutic and diagnostic product sales.

"Most pharma companies currently have access to one or more antibody technologies, therefore the success of a new platform requires significant technical and business advantages. The quality of our output, combined with our ability to reduce complex business issues, such as gate-keeping and burdensome royalty obligations, are key aspects to driving broader collaborations with pharma companies," says Guy van Meter, Senior Director of Business Development of Adimab. "Based on our early success, we believe that Adimab's technology will continue to be in high demand and we are in active discussions with several partners regarding broader unencumbered access and technology transfer."

About Adimab

Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements. For more information, visit <http://www.adimab.com>.

15 December 2010

Adimab, Inc. Announces New Discovery Programs with Eli Lilly and Company (LLY), Genentech (RHHBY) and Human Genome Sciences, Inc. (HGS)

LEBANON, N.H.--(BUSINESS WIRE)-- Adimab, Inc., a technology leader in the discovery of fully human antibodies, today announced the initiation of three new independent research collaborations with Eli Lilly, Genentech, and Human Genome Sciences. Over the past 18 months Adimab has established collaborations with several leading Pharmaceutical companies including: Merck, Roche, Novartis, Pfizer, and now Eli Lilly, Genentech, and Human Genome Sciences.

"As more companies develop therapeutic leads against the same validated disease targets, leading Pharma companies are actively seeking out technologies that give them a meaningful advantage and Adimab's deal flow speaks for itself," said Tillman Gerngross, Adimab's CEO and co-founder. "In this highly competitive environment, having access to the best technology becomes essential, not optional. Our ability to provide high quality leads in a matter of months is driving the demand for our technology."

In addition to the three new collaborations, Adimab announced the achievement of a technical milestone in its ongoing collaboration with Novartis, which was initiated in June of 2010.

Adimab also announced that Merck has exercised its option to start an additional project around a 2nd target.

"Adimab's platform is unique in comparison to any other antibody discovery technology. By incorporating target biology into the selection process we are able to generate very high quality leads in a short timeframe," said Guy Van Meter, Adimab's Senior Director of Business Development. "The most sophisticated buyers in the industry understand the impact Adimab could have on their pipelines. Since launching the platform in June of 2009, we have closed a total of 15 funded discovery programs, including 10 new programs in 2010."

About Adimab's New Discovery Deals

Adimab and Lilly have entered into a collaboration whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against two targets selected by Lilly. For each target, the agreement grants Lilly the right to research antibodies generated from the collaboration for potential use as therapeutic products. Under the terms of the agreement, Adimab will receive various upfront fees including research fees and technical milestones. In addition, for each target, Lilly will have the sole option to exclusively license antibodies from the collaboration, and if Lilly were to exercise the option for a particular target, then Adimab would receive license fees, clinical milestones and royalties on therapeutic product sales for such target.

Adimab and Genentech, Inc., a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) have initiated a research program whereby Adimab will use its proprietary yeast-based antibody discovery platform to identify fully human antibodies against two targets selected by Genentech. Under the terms of the agreement, Genentech has rights to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments, preclinical milestones and licensing fees. In addition, Adimab is eligible to receive clinical development milestones and royalties on therapeutic and diagnostic product sales.

Adimab and Human Genome Sciences, of Rockville MD, have initiated a research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against one target selected by Human Genome Sciences. The agreement gives Human Genome Sciences the option to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments and preclinical milestones. In addition, Adimab is eligible to receive clinical development milestones and royalties on product sales.

About Adimab

Adimab's integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and expressibility. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements. For more information, visit <http://www.adimab.com>.

Filing Data

Not available.

Contract

Not available.